Association Between miR-423 rs6505162 Polymorphism and Susceptibility to Cancer.
Previous studies investigated the impact of miR-423 rs6505162 C>A polymorphism on individual susceptibility to risk, but the conclusions are still controversial and inconclusive. We performed a meta-analysis to get a more precise and comprehensive assessment of the association between miR-423 rs6505162 variant and cancer risk. Relevant studies were identified by searching the PubMed, Web of Science, Scopus and Google scholar databases up to September 03, 2018. Twenty seven case-control studies comprising 10,500 cases and 13,781 controls were included. The strength of correlation between rs6505162 polymorphism and cancer risk was evaluated by odds ratios (ORs) and 95% confidence intervals (CIs) under six genetic models. The findings showed that rs6505162 variant significantly decreased the risk of cancer in heterozygous codominant (OR = 0.88, 95% CI = 0.79-0.97, p = 0.009, AC vs. CC), dominanat (OR = 0.86, 95% CI = 0.77-0.95, p = 0.005, AC + AA vs. CC), and allele (OR = 0.89, 95% CI = 0.82-0.96, p = 0.003, A vs. C) genetic models. Stratified analyses by cancer types revealed that rs6505162 variant significantly decreased the risk of gastrointestinal cancer, colorectal cancer and lung cancer. The variant was not associated with the risk of esophageal cancer, breast cancer and gastric cancer. In addition this variant was associated with protective effect against cancer in Asian population. In conclusion, the findings of this meta-analysis suggests that miR-423 rs6505162 polymorphism may play a role in protection against cancer. More well-designed studies are required to elucidate the exact role of miR-432 polymorphism on cancer development.